A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium–glucose co-transporter 2 (SGLT2) inhibitors improve hyperglycemia, and the usefulness of co-administration of DPP-4 inhibitors and insulin therapy has been well established. However, it has been still uncertain whether combinat...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-07-01
|
Series: | Diabetology & Metabolic Syndrome |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13098-017-0255-8 |